Sells diagnostic instruments and tests for laboratory and point-of-care use, and blood-screening products to healthcare facilities, blood and plasma centers, and consumers.
10-K for FY2025, filed Feb 19, 2026We currently sell our products directly to end users through a direct sales force and through a network of distributors, for professional…View ↗
We manage our business geographically to better align with the market dynamics of the specific geographic regions in which we operate, with…View ↗
Instruments and tests to provide rapid results across a broad continuum of POC settings, including tests for professional healthcare…View ↗
Immunohematology instruments and tests used for blood typing and antibody identification to help confirm patient-donor compatibility in…View ↗
Donor Screening instruments and tests used for blood and plasma screening for infectious diseases for global customers (1) Represents our…View ↗
North America is the largest segment, and revenue comes mainly from product sales paid when products ship or are delivered; customers also pay for service contracts before service is provided.
10-K for FY2025, filed Feb 19, 2026The Company records revenues primarily from product sales. These revenues are recorded net of rebates and other discounts. These rebates…View ↗
The contract asset balance consisted of contractual arrangements with certain customers under which the Company invoices the customers…View ↗
The Company recognizes a contract liability when a customer pays an invoice prior to the Company transferring control of the goods or…View ↗
10-K for FY2025, filed Feb 19, 2026
FY2025 revenue by reportable segment ↗$2.7B
10-K for FY2025, filed Feb 19, 2026
$2.7B ↗| Segment | Share | Revenue | How money arrives |
|---|---|---|---|
|
North America
Sold outright
10-K for FY2025, filed Feb 19, 2026 |
55%
FY2022: 78%
|
North America, FY2025
$1.5B Sources
|
Sold outright |
|
EMEA
Sold outright
10-K for FY2025, filed Feb 19, 2026 |
13%
FY2022: 6.3%
|
EMEA, FY2025
$360.7M Sources
|
Sold outright |
|
China
Sold outright
10-K for FY2025, filed Feb 19, 2026 |
12%
FY2022: 6.7%
|
China, FY2025
$334.7M Sources
|
Sold outright |
|
JPAC
Sold outright
10-K for FY2025, filed Feb 19, 2026 |
11% |
JPAC, FY2025
$293M Sources
|
Sold outright |
|
Latin America
Sold outright
|
9.3% |
Latin America, FY2025
$252.9M Sources
|
Sold outright |
Hospitals, laboratories, clinics and blood or plasma centers buy diagnostic products, alongside retailers and individual consumers. Sales are primarily direct in North America and Western Europe, while emerging markets use direct sales and distributors; distributors also help reach smaller North American point-of-care customers.
10-K for FY2025, filed Feb 19, 2026We currently sell our products directly to end users through a direct sales force and through a network of distributors, for professional…View ↗
Our sales team is comprised of highly skilled and experienced professionals. We sell products globally and market and distribute products…View ↗
In North America, we use a sales force for each of our business units. Our North America distribution strategy takes into account the…View ↗
10-K for FY2025, filed Feb 19, 2026
For both fiscal years ended 2025 and 2024, one customer represented 11% of Total revenues in the North America segment. For fiscal year…View ↗
No. It lost $1.1B in FY2025.
10-Q for Q3 FY2026, filed Nov 4, 2026
−$53.8MView ↗
10-Q for Q3 FY2026, filed Nov 4, 2026
Open tableView ↗
8-K, filed Aug 6, 2026
“Our second quarter performance demonstrated QuidelOrtho’s underlying strength and the benefits of our diversified portfolio, with solid…View ↗
8-K, filed Jun 23, 2026
SAN DIEGO, CA — QuidelOrtho Corporation (Nasdaq: QDEL) (“QuidelOrtho” or the “Company”), a leading global provider of diagnostic solutions…View ↗
U.S. donor screening
The older report described donor-screening instruments and tests for blood and plasma screening globally. The latest says QuidelOrtho is winding down its U.S. portfolio while continuing donor screening elsewhere.
10-K for FY2022, filed Feb 23, 2023 10-K for FY2025, filed Feb 19, 2026Donor screening instruments and tests used for blood and plasma screening for infectious diseases for global customersView ↗
In February 2024, we initiated a wind-down plan to transition out of the U.S. donor screening portfolio. Specifically, we are winding-down…View ↗
Competes with Abbott Laboratories, bioMérieux, Bio-Rad, Danaher, Diasorin, Hologic, Qiagen, Revvity, Roche, Siemens Healthineers, Thermo Fisher Scientific, Waters, and Wermerson Immuncor
10-K for FY2025, filed Feb 19, 2026There is significant competition in the development and marketing of IVD products, and innovation, product development, regulatory…View ↗
Loading...